

DAFTAR PUSTAKA

1. Tang LL, Chen WQ, Xue WQ, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. *Cancer Lett.* 2016;374(1):22-30.
2. Wah S, Ling Y, Man C, et al. Etiological factors of nasopharyngeal carcinoma. *Oral Oncol.* 2014;50(5):330-8.
3. He J, Jia W, Fan Q, et al. Genetic polymorphisms of TLR3 are associated with Nasopharyngeal carcinoma risk in Cantonese population. *BMC Cancer.* 2007;7:1-7.
4. Rahman S. Disertasi Hubungan DNA Virus Epstein-Barr, Alel HLA-DRB1 dan Polimorfisme Gen CYP2E1 Dengan Kejadian Karsinoma Nasofaring Pada Etnik Minangkabau. Universitas Andalas. 2019.
5. Adham M, Gondhowiarjo S, Soediro R et al. *Pedoman Nasional Pelayanan Kedokteran Kanker Nasofaring.* Kementerian Kesehatan Republik Indonesia. Jakarta. 2017.
6. Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *A Cancer J Clin.* 2018;68:394-424.
7. Wim Z. Profil Penderita Karsinoma Nasofaring dan Uji Diagnostik Pemeriksaan FNAB (Fine Needle Aspiration Biopsy) Karsinoma Nasofaring Metastase Kelenjar Getah Bening Colli di Instalasi Patologi Anatomi RSSA. Universitas Brawijaya Knowlegde Garden. 2015.
8. Diva P, Suta D, Andi K, Saputra D, Wulan S, Sutanegara D. Profil Penderita Kanker Nasofaring Di Rumah Sakit Umum Pusat Sanglah Denpasar Periode Januari – Desember Tahun 2014. *E-Jurnal Med.* 2019;8(2):1-14.
9. Naomi SM, Dewi YA, Agustina H, Naomi SM, Dewi YA, Agustina H. Association between Histopathological Grading and Clinical Staging in Nasopharyngeal Carcinoma Hubungan Derajat Histopatologi dengan Stadium Klinis pada Karsinoma Nasofaring ** Departemen Telinga Hidung Tenggorokan-Kepala Leher. *J Med Heal.* 2018;2(2):730-7.
10. Adelisa R. Profil Penderita Karsinoma Nasofaring Pada Pasien Rawat Inap di RSUD DR.Zainoel Abidin Banda Aceh Periode 2017-2019. ETD Unsyiah.
11. Sriwijaya MK, Dawolo AP, Utama DS, Kasim BI, Selatan C, Insiden T. Profil Klinis Karsinoma Nasofaring di Departemen THTKL RSUP Dr . Mohammad Hoesin Palembang Tahun 2014-2015. *Maj Kedokt Sriwij.* 2017:1-9.
12. Melani W, Sofyan F. Karakteristik Penderita Kanker Nasofaring di Rumah Sakit H . Adam Malik Medan Tahun 2011. *E-Jurnal FK-USU.* 2013;1(1):1-5.
13. Faiza S, Rahman S, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *J Kesehat Andalas.* 2013;5(1):90-6.
14. Xie SH, Yu IT sun, Tse LA, Au JSK, Lau JSM. Tobacco smoking, family history, and the risk of nasopharyngeal carcinoma: a case–referent study in Hong Kong Chinese. *Cancer Causes Control.* 2015;26(6):913-21.
15. Lin JH, Jiang CQ, Ho SY, et al. Smoking and nasopharyngeal carcinoma

- mortality: A cohort study of 101,823 adults in Guangzhou, China. *BMC Cancer*. 2015;15(1):1-7.
16. Lourembam DS, Singh AR, Sharma TD, Singh S, Singh TR, Singh LS. Evaluation of Risk Factors for Nasopharyngeal Carcinoma in a High-risk Area of India , the Northeastern Region. *Asian Pacific J cancer Prev*. 2015;16:4927-35.
 17. Ruuskanen M, Leivo I, Minn H, et al. Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma. *BMC Cancer*. 2019;19(1):1-12.
 18. Qin H, Yao Y. From Family Study to Population Study: A History of Genetic Mapping for Nasopharyngeal Carcinoma (NPC). *Appl Comput Genomics*.2018:81-106.
 19. He YQ, Xue WQ, Shen GP, Tang LL, Zeng YX, Jia WH. Household inhalants exposure and nasopharyngeal carcinoma risk: A large-scale case-control study in Guangdong, China. *BMC Cancer*. 2015;15(1):1-8.
 20. Vérillaud B, Gressette M, Morel Y, et al. Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic. *Infect Agent Cancer*. 2012;7(1):36.
 21. Teow S-Y, Yap H-Y, Peh S-C. Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment. *J Pathog*. 2017;2017:1-10.
 22. Tsang CM, Tsao SW. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. *Virol Sin*. 2015;30(2):107-21.
 23. Chou J, Lin Y, Kim J et al. Nasopharyngeal Carcinoma-Review Of The Molecular Mechanism of Tumorigenesis. *Head Neck*. 2008;23(1):1-7.
 24. Wang B, Yi D, Liu Y. TLR3 gene polymorphisms in cancer : a systematic review and meta-analysis. *Chin J Cancer*.2015:1-13.
 25. Gnjatic S, Sawhney N, Bhardwaj N. Toll-Like Receptor Agonists : Are They Good Adjuvants? *Cancer J*. 2010;;382-91.
 26. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: A double-edged sword for defense and offense. *Arch Pharm Res*. 2012;35(8):1297-316.
 27. Nomi N, Kodama S, Suzuki M. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. *Oncol Rep*. 2010;24:225-31.
 28. Schröder M, Bowie AG. TLR3 in antiviral immunity: Key player or bystander? *Trends Immunol*. 2005;26(9):462-8.
 29. Mounad K, Lascorz J, Bevier M, Khyatti M, Ennaji MM. Genetic Polymorphisms in Host Innate Immune Sensor Genes and the Risk of Nasopharyngeal Carcinoma in North Africa. *Genet Immunity*. 2013;3:971-7.
 30. Cheng D, Hao Y, Zhou W, Ma Y. Association between Toll-like receptor 3 polymorphisms and cancer risk : a meta-analysis. *Int Soc ofOncology BioMarkers*. 2014;3:1-10.
 31. Sudoyo AW. Kanker kolorektal usia muda etnik Jawa , Sunda , Makassar , dan Minang di Indonesia : Kajian klinikopatologi dan imunohistokimia instabilitas mikrosatelit.
<http://lib.ui.ac.id/detail?id=20425663&lokasi=lokal>.

32. Harahap WA, Arisanty D, Khambri D, Mubarika S, Diskusi H. Metilasi Promoter Gen BRCA1 dan Pengaruhnya terhadap Karakteristik Kanker Payudara Premenopause Sporadik Etnis Minang. *Cermin Dunia Kedokt.* 2015;42(3):186-90.
33. Sari J. Tesis Hubungan Alel Human Leukocyte Antigen A*11 dengan Kejadian Karsinoma Nasofaring Pada Etnik Minangkabau di RSUP DR. M. Djamil Padang. Universitas Andalas. 2019.
34. Grewin D. Tesis Perbedaan Alel Human Leukocyte Antigen A*02 Antara Pasien Karsinoma Nasofaring Dengan Kontrol Etnik Minangkabau. Universitas Andalas. 2019.
35. Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011. Rosetta Stone for NPC: Genetics, viral infection, and other environmental factors. *Semin Cancer Biol.* 2012;22(2):107-16.
36. Ozkan AD, Kaleli HN, Kaleli S. A key receptor in apoptosis : Toll-like receptor 3 (TLR3). *J Mol Oncol Res.* 2019;3:1-5.
37. Baratawidjaja K, Rengganis I. Gambaran Umum Sistem Imun. In: Baratawidjaja K, Rengganis I, eds. *Imunologi Dasar*. 12th ed. Badan Penerbit FKUI; 2018:23-52.
38. Chijioke O, Azzi T, Nadal D, Münz C. Innate immune responses against Epstein Barr virus infection. *J Leukoc Biol.* 2013;94(6):1185-90.
39. Gosu V, Son S, Shin D, Song K. Insights into the dynamic nature of the dsRNA-bound TLR3 complex. *Sci Rep.* 2019;1-14.
40. Maglione PJ, Simchoni N, Cunningham-rundles C. Toll-like receptor signaling in primary immune deficiencies. *Ann N Y Acad Sci.* 2015;1-21.
41. Pandey S, Singh S, Anang V, Bhatt AN, Natarajan K, Dwarakanath BS. Pattern Recognition Receptors in Cancer Progression and Metastasis. *Cancer Growth Metastasis.* 2015;8:25-34.
42. Khan A, Khan Z, Warnakulasuriya S. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence? *Ann Oncol.* 2016;27:416-22.
43. Yeh WC, Chen NJ. Immunology - Another toll road. *Nature.* 2003;424(6950):736-7.
44. Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. *Hum Immunol.* 2011;72(11):1095-1116.
45. Matijevic T, Pavelic J. Toll-Like Receptors : Cost or Benefit for Cancer ? *Curr Pharm Des.* 2010;16:1081-90.
46. Matsumoto M, Oshiumi H, Seya T. Antiviral responses induced by the TLR3 pathway. *Rev Med Virol.* 2011;18:305-19.
47. Zhang SY, Herman M, Ciancanelli MJ, et al. TLR3 immunity to infection in mice and humans. *Curr Opin Immunol.* 2013;25(1):19-33.
48. Salaun B, Coste I, Risoan M-C, Lebecque SJ, Renno T. TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells. *J Immunol.* 2006;176(8):4894-901.
49. Yu L, Wang L, Chen S. Dual character of Toll-like receptor signaling: Pro-tumorigenic effects and anti-tumor functions. *Biochim Biophys Acta - Rev Cancer.* 2013;1835(2):144-54.

50. Poh SS, Chua MLK, Wee JTS. Carcinogenesis of nasopharyngeal carcinoma: An alternate hypothetical mechanism. *Chin J Cancer*. 2016;35(1):1-9.
51. Kamran S, Riaz N, Lee N. Nasopharyngeal carcinoma. *Surg Oncol Clin*. Published online 2015:547-61.
52. Soo L, Tan Y, Wong B, et al. Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma. *Onco Immunol*. 2018;7(11):1-12.
53. Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in indonesia: Epidemiology, incidence, signs, and symptoms at presentation. *Chin J Cancer*. 2012;31(4):185-96.
54. Cheesman A. Pharynx. In: Brennan P, Mahadevan V, Evans B, eds. *Clinical Head and Neck Anatomy for Surgeons*. 1st ed. Taylor & Francis Group; 2016:181-93.
55. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. *Lancet*. 2016;387(10022):1012-24.
56. Paulsen F, Waschke J. Pharynx. In: Paulsen F, Waschke J, eds. *Sobotta Atlas of Human Anatomy Head, Neck and Neuroanatomy*. 15th ed. Elsevier GmbH; 2011:172-9.
57. Virus B, Tsang CM, Lo KW, Nicholls JM, Huang SCM, Tsao SW. Pathogenesis of Nasopharyngeal Carcinoma : *Elsevier*. 2019:45-64.
58. Shah J, Patel S, Singh B. Pharynx and Esophagus. In: Shah J, Patel S, Singh B, eds. *Jatin Shah's Head and Neck Surgery and Oncology*. 4th ed. Elsevier Mosby; 2012:290-355.
59. Jangra S, Yuen KS, Botelho MG, Jin DY. Epstein-barr virus and innate immunity: Friends or foes? *Microorganisms*. 2019;7(6):1-23.
60. Umar B, Ahmed R. Nasopharyngeal carcinoma, an analysis of histological subtypes and their association with EBV, a study of 100 cases of Pakistani population. *Asian J Med Sci*. 2014;5(4):16-20.
61. Yang ZH, Dai Q, Gu YJ, Guo QX, Gong L. Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma. *Cancer Sci*. 2012;103(4):653-8.
62. Mahdavifar N, Towhidi F, Makhsofi BR, et al. Incidence and Mortality of Nasopharynx Cancer and Its Relationship With Human Development Index in the World in 2012. *World J Oncol*. 2016;7(5-6):109-18.
63. Petersson F. Nasopharyngeal carcinoma: A review. *Semin Diagn Pathol*. 2015;32(1):54-73.
64. Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. *Osong Public Heal Res Perspect*. 2016;7(6):360-72.
65. Beigzadeh Z, Pourhassan B, Kalantary S, Golbabaie F. Occupational exposure to wood dust and risk of nasopharyngeal cancer: A systematic review and meta-analysis. *Environ Res*. 2019;171(June 2018):170-6.
66. Arslan N, Tuzuner A, Koyucu A, Dursun S, Hucumenoglu S. The role of nasopharyngeal examination and biopsy in the diagnosis of malignant diseases. *Braz J Otorhinolaryngol*. 2019;85(4):481-5.
67. Baratawidjaja K, Rengganis I. Imunologi Tumor. In: Baratawidjaja K,

- Rengganis I, eds. *Imunologi Dasar*. 12th ed. Badan Penerbit FKUI; 2018:407-32.
68. Tsao SW, Tsang CM, Lo KW. Epstein – Barr virus infection and nasopharyngeal carcinoma. *R Soc Publ*. 2017:1-15.
 69. Veyrat M, Durand S, Classe M, et al. Stimulation of the toll-like receptor 3 promotes metabolic reprogramming in head and neck carcinoma cells. *Impact Journals Oncotarget*. 2016;7(50):82580-82593.
 70. Santos DJ da S, Palomares NB, Quintão CCA, Normando D. Race versus ethnicity: Differing for better application. *Dental Press J Orthod*. 2010;15(3):121-4.
 71. Navis A. Sejarah. In: Navis A, ed. *Alam Terkembang Jadi Guru*. 1st ed. PT Pustaka Gratifikasi; :1-44.
 72. Statistik BP. *Kewarganegaraan, Suku Bangsa Dan Bahasa Sehari-Hari Penduduk Indonesia*. Badan Pusat Statistik. Jakarta; 2010.
 73. Rozi S. Konstruksi Identitas Agama Dan Budaya Etnis Minangkabau Di Daerah Perbatasan: Perubahan Identitas Dalam Interaksi Antaretnis Di Rao Kabupaten Pasaman Sumatera Barat. *J Masy Indones*. 2013;39(1):215-45.
 74. Connelly R, Gayle V, Lambert PS. Ethnicity and ethnic group measures in social survey research. *Methodol Innov*. 2016;9:1-10.
 75. Lin SS, Kelsey JL. Use of race and ethnicity in epidemiologic research: Concepts, methodological issues, and suggestions for research. *Epidemiol Rev*. 2000;22(2):187-202.
 76. Madiyono B, Moeslichan S, Sastroasmoro S et al. Perkiraan Besar Sampel. In: Sastroasmoro S, Ismael S, eds. *Dasar-Dasar Metodologi Penelitian Klinis*. 5th ed. Sagung Seto; 2014:352-87.
 77. Dahlan M. Besar Sampel Aksis Komparatif 79-93. In: Dahlan M, ed. *Besar Sampel Dalam Penelitian Kedokteran Dan Kesehatan*. 5th ed. PT Epidemiologi Indonesia; 2019:79-93.
 78. Wu SG, Liao XL, He ZY, et al. Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis. *Oral Oncol*. 2017;73:83-7.
 79. Shield KD, Ferlay J, Jemal A, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. *CA Cancer J Clin*. 2017;67(1):51-64.
 80. Peterson BR, Nelson BL. Nonkeratinizing Undifferentiated Nasopharyngeal Carcinoma. *Head Neck Pathol*. 2013;7(1):73-5.
 81. Wang W, Feng M, Fan Z, Li J, Lang J. Clinical outcomes and prognostic factors of 695 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. *Biomed Res Int*. 2014:1-10
 82. Chan ATC. Nasopharyngeal carcinoma. *Ann Oncol*. 2010;21:308-12.
 83. Ma L, Tang FY, Chu WK, et al. Association of toll-like receptor 3 polymorphism rs3775291 with age-related macular degeneration: A systematic review and meta-analysis. *Sci Rep*. 2016;6:1-7.
 84. Edwards AO, Chen D, Fridley BL, et al. Toll-like receptor polymorphisms and age-related macular degeneration. *Investig Ophthalmol Vis Sci*. 2008;49(4):1652-9.
 85. Assmann TS, De Almeida Brondani L, Bauer AC, Canani LH, Crispim D.

Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. *Eur J Endocrinol.* 2014;170(4):519-27.

86. Bin Y, Wang X, Zhao L, Wen P, Xia J. An analysis of mutational signatures of synonymous mutations across 15 cancer types. *BMC Med Genet.* 2019;20:1-10.



